This study tested the effect of roflumilast, a selective PDE4 inhibitor approved by FDA for the treatment of chronic obstructive lung disease, and its active metabolite RNO, on AQP2 regulation in the kidney IMCD. The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.